July 11, 2026 — Millions of Americans taking Ozempic and Wegovy for diabetes and weight loss are already aware of the gastroparesis lawsuits that have flooded federal courts. But a second, equally alarming wave of litigation is now gaining serious momentum — one tied not to stomach damage, but to permanent vision loss.
In federal court in Philadelphia, a separate multidistrict litigation has been established specifically for patients who developed NAION — non-arteritic anterior ischemic optic neuropathy — a form of vision loss linked in published medical research to the GLP-1 receptor agonist drugs that include Ozempic, Wegovy, Mounjaro, and Zepbound. The MDL is growing, a court-supervised Science Day was conducted in June 2026, and bellwether trials are expected to begin as early as late 2026.
For patients who lost vision while on one of these drugs and didn’t know a lawsuit was possible, here is what the litigation looks like right now — and what you need to do.
Two MDLs, Two Injury Tracks
The GLP-1 receptor agonist litigation has officially split into two separate federal multidistrict litigations, both presided over by Judge Karen S. Marston in the Eastern District of Pennsylvania.
MDL No. 3094 — Gastrointestinal Injuries. This MDL covers plaintiffs who developed severe GI complications — gastroparesis (stomach paralysis), ileus, bowel obstruction, and similar conditions — while taking Ozempic, Wegovy, Mounjaro, or Zepbound. As of July 2026, this MDL contains 3,848 active cases, making it one of the larger pharmaceutical MDLs currently active in the federal system. The core allegations: Novo Nordisk and Eli Lilly failed to adequately warn patients and prescribers about the risk of severe, potentially permanent GI injuries.
MDL No. 3163 — Vision Loss (NAION). This MDL was created after research published in a leading medical journal identified a significant link between semaglutide use and NAION. As of July 2026, there are 86 cases pending in this MDL. That number is still small — but the same was true of the GI MDL in its early months. In New Jersey, plaintiffs have also successfully consolidated vision loss claims into multicounty litigation. A Science Day — where medical experts and lawyers presented evidence on the biological mechanism of NAION to Judge Marston — was held in June 2026, a critical pretrial milestone.
What Is NAION — and Why Is It Serious?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It is caused by reduced blood flow to the front portion of the optic nerve, leading to swelling and subsequent nerve damage. NAION typically strikes suddenly — patients describe waking up one morning with a dark patch, blurred section, or complete loss of vision in one eye. It is usually painless, which can delay the realization that something serious is happening.
There is no treatment that reverses NAION once it has occurred. The vision loss it causes is generally permanent. Some patients experience partial loss — a diminished visual field or reduced sharpness. Others lose functional vision in the affected eye entirely. In rare cases, both eyes are eventually affected.
NAION was already a known risk in patients with diabetes, hypertension, sleep apnea, and other conditions that impair blood flow. What the new litigation argues is that GLP-1 receptor agonist drugs — specifically semaglutide, the active ingredient in Ozempic and Wegovy — dramatically increase that risk above and beyond what the underlying condition would cause.
The Research Behind the Lawsuits
The legal claims are anchored in a study published in the New England Journal of Medicine — one of the most prestigious medical journals in the world. Researchers at Massachusetts Eye and Ear, a Harvard Medical School affiliate, analyzed patient records and found that individuals taking semaglutide were significantly more likely to develop NAION than similar patients on other diabetes or obesity medications.
Specifically, the researchers found:
- Among patients with type 2 diabetes, those on semaglutide had a 4.28-fold higher risk of NAION compared to those on other diabetes drugs.
- Among patients using the drugs for obesity or weight management, those on semaglutide had a 7.64-fold higher risk of NAION compared to those on other obesity treatments.
The proposed biological mechanism involves semaglutide’s effects on fluid regulation and vasculature — changes in intracranial pressure or blood flow patterns that may compromise circulation to the optic nerve in susceptible patients. Plaintiffs argue that this risk was detectable through the drug’s own clinical trial data and post-market surveillance, and that Novo Nordisk failed to disclose it or add adequate warnings to the labeling.
Where the Litigation Stands Right Now
Both MDLs are still in early stages. No global settlement has been announced for either track. Bellwether trials — the small group of representative cases that go to trial first, whose outcomes help set expectations for settlement values across the broader MDL — are not expected to begin until late 2026 or early 2027 for the GI injury track, with the vision loss track likely to follow.
The Science Day held before Judge Marston in June 2026 was a pivotal moment for the vision loss MDL. At Science Day proceedings, opposing expert witnesses present the medical evidence and competing scientific theories to the judge in a structured, focused format. The judge’s assessment of the science — while not a ruling on individual cases — shapes how aggressively defendants will fight or settle, and signals to both sides what expert theories are likely to hold up at trial.
The growth of the New Jersey MCL for vision loss claims is a parallel development. Some plaintiffs prefer state court consolidation over federal MDL when it offers procedural advantages — and the NJ consolidation moving forward signals that plaintiffs’ attorneys believe the legal theory is viable enough to pursue on multiple fronts.
What These Cases Could Be Worth
It is early in the litigation and no settlement amounts have been established. But legal analysts who track pharmaceutical MDLs have offered preliminary projections based on the nature of the injuries and comparable litigation.
For the GI injury track, cases involving severe gastroparesis — particularly those requiring gallbladder removal or other surgical intervention — have been projected in the range of $400,000 to $700,000 per case, depending on severity, duration of injury, and impact on quality of life.
For vision loss cases, projected values are generally higher — potentially exceeding $1,000,000 per case — because NAION-caused vision loss is permanent. A person who loses significant vision in one or both eyes while in their 30s, 40s, or 50s faces decades of impaired ability to work, drive, read, and engage in daily activities. When permanent disability, lost earning capacity, and long-term care needs are factored into damages, DisabilityExchange.org notes that plaintiffs facing life-altering permanent conditions often benefit from coordinating legal recovery with disability benefits planning — especially when SSDI eligibility may also be in play for those who can no longer work. Catastrophic injury verdicts involving permanent loss of sensory function routinely exceed seven figures.
These are projections, not guarantees. What individual cases are worth will depend on the specific facts, the available insurance and defendant assets, and how bellwether trials unfold.
Who Can File an Ozempic Vision Loss Claim?
You may have a viable claim if:
- You took Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 receptor agonist drug
- You were diagnosed with NAION (non-arteritic anterior ischemic optic neuropathy) while on the medication or within a reasonable time after stopping it
- You experienced sudden vision loss, a dark or missing section in your visual field, or significant changes in vision that were diagnosed by an ophthalmologist or neurologist
It does not matter whether you were taking the drug for diabetes or weight loss. It also does not automatically disqualify you if you had other risk factors for NAION — the litigation specifically addresses the elevated risk that semaglutide adds on top of any baseline risk.
Patients with underlying conditions that predispose them to NAION — diabetes, hypertension, high cholesterol, sleep apnea — are actually among the most common Ozempic and Wegovy users. If those patients developed NAION while on the drug at a rate significantly higher than similar patients not on the drug, the causation argument is strengthened, not weakened.
What to Do If You Think You Were Affected
If you or someone you know lost vision while taking Ozempic, Wegovy, or a similar GLP-1 drug, the most important steps are:
- See an ophthalmologist immediately if you haven’t already. A formal NAION diagnosis is essential to any legal claim. Make sure your vision loss is documented in medical records with the specific diagnosis.
- Preserve your prescription records. Gather pharmacy records, prescription labels, insurance records, and any documentation showing what drug you were taking, the dose, and the dates of use.
- Document the timeline. Write down when you first noticed vision changes, what symptoms you experienced, and when you received your diagnosis. The closer in time your vision loss was to your drug use, the stronger the temporal connection in your case.
- Do not give recorded statements to the manufacturer or their insurers. If anyone from Novo Nordisk or Eli Lilly — or their representatives — contacts you asking about your health history or drug use, speak with a lawyer first.
- Act before the statute of limitations runs. Personal injury claims — including pharmaceutical product liability claims — have filing deadlines that vary by state, typically two to three years from when you knew or should have known your injury was linked to the drug. Missing this deadline bars your claim permanently.
Finding the Right Lawyer for an Ozempic Vision Loss Claim
Mass tort pharmaceutical litigation is specialized work. The attorneys handling Ozempic and Wegovy cases are experienced in pharmaceutical product liability, MDL procedure, and working with expert witnesses on complex causation questions. Individual personal injury attorneys who do not practice in this area are generally not the right fit.
Look for law firms that:
- Are actively accepting Ozempic NAION or vision loss cases — not all firms handling the GI injury claims are also handling vision loss
- Have experience in pharmaceutical MDLs and mass torts
- Work on a contingency fee basis — you owe nothing upfront, and legal fees come from your recovery
- Can explain exactly where your case would be filed and how it relates to the current MDL proceedings
Legal Giant’s guide to the Ozempic lawsuit covers the full background on both the GI injury claims and what makes these cases viable. For broader context on how pharmaceutical injury lawsuits work, see our guide on pharmaceutical injury lawyers. If the vision loss has left you unable to work or considering long-term disability, our overview of catastrophic injury claims addresses how these cases are valued when the harm is permanent.
The Bottom Line
The Ozempic and Wegovy litigation is no longer just a stomach injury story. The vision loss MDL has crossed a threshold that signals serious legal momentum — a Science Day before the presiding judge, a New Jersey state court consolidation, and bellwether trials on the horizon. For patients who went blind or lost significant vision while on these drugs, the window to file a claim is open now, but it will not stay open forever.
The drug’s benefits in managing diabetes and obesity are real and well-documented. But so is the published medical evidence linking semaglutide to a dramatically elevated risk of irreversible vision loss. The legal system’s job is to determine whether that risk should have been disclosed — and whether the companies that made these drugs bear financial responsibility for the patients who weren’t warned.
